生物制药设备供应商Sartoriushas acquired a 10% stake in 3D bioprinting innovator比科.
Alongside Sartorius’ €45 million share acquisition, the firms have announced a collaboration that’ll see them work together on R&D initiatives, and come up with ‘digital solutions for cell line development workflows.’ As part of the deal, Sartorius has also become a BICO distributor in the APAC region, a move that according to BICO CEO Erik Gatenholm, will “expand its presence and accelerate growth.”
Gatenholm解释说：“ BICO将获得增值，互补技术和产品，这将增强我们在生物启动和实验室自动化中的当前客户产品。”“我们将BICO中的Sartorius所有权视为对BICO增长战略的验证。”
BICO从2022年岩石的反弹
Previously known as CELLINK, BICO began in 2016 with a strong focus on 3D bioprinting, but it has expanded into related fields through acquisitions in recent years. Between 2020 and 2021,BICO购买了Mattek Corporation,Nanoscribe， 和分数, among a string of other additions to its portfolio, as part of a strategy of ‘bioconvergence.’
Last year, however, the company was shaken by mismanagement allegations raised against Gatenholm by a former employee. In an瑞典出版物Dagens Industri发行的文章，前BICO CFO Gusten Danielsson批评Gatenholm，称他不是领导该公司的合适人选，而消息人士还声称，内部有“有关其管理风格的投诉”。
在当时发出的声明中BICO宣布它具有“完全信心” Gatenholm，但这并没有阻止其股价在丹尼尔森辞职后下跌41％。从那时起，该公司的股票从27.40秒的低点逐渐反弹到104.70 sek，现在已经获得了萨托里乌斯的重要新投资者。
Sartoriusand BICO’s partnership
萨托里乌斯（Sartorius）总部位于德国哥廷根（Göttingen），已成为生命科学行业的主要参与者。最后，该公司拥有15,000名劳动力，在60多个国家 /地区运营，年收入超过34亿欧元，其中79％来自BioProcess Solutions，而实验室产品和服务则21％。
除了生物反应器和流体管理解决方案之类的设备外，Sartorius还将其服务作为研究合作伙伴，为从事抗体，免疫学和神经科学R＆D的研究合作伙伴。尽管该公司没有明确提供3D生物打印服务，但它说它确实“继续与印刷提供商合作”，以期开发诸如Ordarysoids之类的“新型生物系统”。
萨托里乌斯（Sartorius）在这一领域的最新努力使其不仅将其在BICO的股份增加到10.1％，而且同意与该公司进行“全面的技术与营销合作”。展望未来，预计这些公司将在3D Bioprinting Research上进行合作，而BICO也通过Sartorius的广泛转售者网络获得了更好地进入APAC市场。
“The cooperation with BICO will enable us to jointly strengthen our activities in very dynamic fields like advanced cell models and digital workflows in drug research and development,” added Gerry Mackay, a member of Sartorius’ Executive Board and Head of its Lab Products & Services Division. “We will further enhance the position of both companies in the fast-growing Asian markets with highly differentiating and relevant technologies.”
“We are convinced that the strategic partnership and the investment in BICO will create value for both parties.”
投资3D生物打印增长
As 3D bioprinting research continues to gather pace, the technology’s drug development and personalized therapy potential have increasingly attracted investment from outside the field. Just last year,核raised another $15.5 millionin Series B funding towards the development of an ‘eProtein’ 3D bioprinter that could help accelerate drug discovery.
在2022年，Regemat 3D还筹集了超过500,000欧元in equity crowdfunding to ramp up the marketing and development of its proprietary bioprinting technology. With further R&D, the firm believes its offering could enable the creation of custom, functional tissues, for treating patients, curing diseases and improving people’s quality of life.
在其他地方，在更宽的3D打印空间中，3D系统已脱离系统性生物, a new bioprinting subsidiary. Systemic Bio is now essentially utilizing the technologies developed as part of its parent firm’s打印到灌注计划以及其他子公司Alevi，到来自人类细胞的3D生物构图血管化模型。
要了解最新的3D印刷新闻，请不要忘记订阅3D打印行业newsletter或跟随我们推特或喜欢我们的页面Facebook.
While you’re here, why not subscribe to ourYouTube渠道？包括讨论，汇报，视频短裤和网络研讨会重播。
Are you looking for a job in the additive manufacturing industry? Visit3D Printing Jobsfor a selection of roles in the industry.
特色图像显示了使用BICO基于挤出的Bio X 3D Bioprointer的工程师。通过BICO照片。
